A Phase II Study of Vindesine in the Treatment of Esophageal Carcinoma
lizuka, Toshifumi; Kakegawa, Teruo; Ide, Hiroko; Ando, Nobutoshi; Watanabe, Hiroshi; Mori, Shozo; Sasaki, Kouichi; Takagi, Iwao; Nashimoto, Atsushi; Ishida, Kaoru; Arimori, Masaki; lizuka Toshifumi; Department of Surgery, National Cancer Center Hospital; Kakegawa Teruo; Department of Surgery, Faculty of Medicine, Kurume University; Ide Hiroko; Department of Surgery, Tokyo Women's Medical College; Ando Nobutoshi; Department of Surgery, Faculty of Medicine, Keio University; Watanabe Hiroshi; Department of Surgery, National Cancer Center Hospital; Mori Shozo; Department of Surgery, Faculty of Medicine, Tohoku University; Sasaki Kouichi; Department of Surgery, Faculty of Medicine, Niigata University; Takagi Iwao; Department of Surgery, Aichi Cancer Center Hospital; Nashimoto Atsushi; Department of Surgery, Niigata Cancer Center; Ishida Kaoru; Department of Surgery, Iwate Medical College; Arimori Masaki; Department of Surgery, Tokyo Second National Hospital
Журнал:
Japanese Journal of Clinical Oncology
Дата:
1989
Аннотация:
A phase II study of Vindesine for esophageal carcinoma was carried out cooperatively by 10 Japanese institutions. Fifty patients were enrolled in the study over a year and ten months. Four patients could not be evaluated because less than 4 weeks had elapsed since their preceding therapy. There were one complete remission and five partial remissions among the 46 remaining patients, a response rate of 13.0%. The patient experiencing the complete remission is still alive more than 24 months after treatment. The main side effects were depilation, anorexia, stomatitis and leukopenia. Thrombocytopenia and elevations of blood urea nitrogen and creati-nine were not marked. There was no mortality connected with the administration of Vindesine. It was concluded that Vindesine is useful in the treatment of esophageal carcinoma as a single agent
274.7Кб